A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes

Mine Harada; Tsunefumi Shibuya; Takanori Teshima; Masahiro Murakawa; Takashi Okamura; Yoshiyuki Niho; Hisashi Gondo; Shin Hayashi; Koichi Akashi; Kazuo Tamura; Shigeyoshi Makino; Hideyo Natori; Koichiro Egami; Shusuke Hisano; Eiji Morioka; Shuichi Taniguchi; Kazuo Yamazaki; Yujiro Yamano; Fusayuki Omori

doi:10.1016/0145-2126(93)90066-T

A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes

Mine Harada, Tsunefumi Shibuya, Takanori Teshima, Masahiro Murakawa, Takashi Okamura, Yoshiyuki Niho, Hisashi Gondo, Shin Hayashi, Koichi Akashi, Kazuo Tamura, Shigeyoshi Makino, Hideyo Natori, Koichiro Egami, Shusuke Hisano, Eiji Morioka, Shuichi Taniguchi, Kazuo Yamazaki, Yujiro Yamano, Fusayuki Omori

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

We performed a randomized phase II trial comparing low-dose aclarubicin (LC-ACR) with very low-dose cytosine arabinoside (VLD-AC) in 39 consecutive untreated patients with myelodysplastic syndromes (MDS), including refractory anemia (RA), RA with excess of blasts (RAEB) and RAEB in transformation (RAEB-t). Nineteen patients received the VLD-AC therapy; 2 good responses (GR) and 2 partial responses (PR) were obtained in 11 patients with RAEB and RAEB-t, while 2 PR were obtained in 8 RA patients. Eighteen patients received the LD-ACR therapy; 2 GR and 4 PR were obtained in 11 RAEB/RAEB-t patients while 2 PR in 7 RA patients. There was no significant difference in the therapeutic effects and survival between these two groups of patients. These observations suggest that the LD-ACR therapy is effective in some patients with MDS and can be used as an alternative to the low-dose Ara-C therapy.

Original language	English
Pages (from-to)	629-632
Number of pages	4
Journal	Leukemia Research
Volume	17
Issue number	8
DOIs	https://doi.org/10.1016/0145-2126(93)90066-T
Publication status	Published - Aug 1993
Externally published	Yes

All Science Journal Classification (ASJC) codes

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0145-2126(93)90066-T

Cite this

Harada, M., Shibuya, T., Teshima, T., Murakawa, M., Okamura, T., Niho, Y., Gondo, H., Hayashi, S., Akashi, K., Tamura, K., Makino, S., Natori, H., Egami, K., Hisano, S., Morioka, E., Taniguchi, S., Yamazaki, K., Yamano, Y., & Omori, F. (1993). A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes. Leukemia Research, 17(8), 629-632. https://doi.org/10.1016/0145-2126(93)90066-T

Harada, M, Shibuya, T, Teshima, T, Murakawa, M, Okamura, T, Niho, Y, Gondo, H, Hayashi, S, Akashi, K, Tamura, K, Makino, S, Natori, H, Egami, K, Hisano, S, Morioka, E, Taniguchi, S, Yamazaki, K, Yamano, Y & Omori, F 1993, 'A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes', Leukemia Research, vol. 17, no. 8, pp. 629-632. https://doi.org/10.1016/0145-2126(93)90066-T

@article{c120d46c00be4806bed1da872cacf0e9,

title = "A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes",

abstract = "We performed a randomized phase II trial comparing low-dose aclarubicin (LC-ACR) with very low-dose cytosine arabinoside (VLD-AC) in 39 consecutive untreated patients with myelodysplastic syndromes (MDS), including refractory anemia (RA), RA with excess of blasts (RAEB) and RAEB in transformation (RAEB-t). Nineteen patients received the VLD-AC therapy; 2 good responses (GR) and 2 partial responses (PR) were obtained in 11 patients with RAEB and RAEB-t, while 2 PR were obtained in 8 RA patients. Eighteen patients received the LD-ACR therapy; 2 GR and 4 PR were obtained in 11 RAEB/RAEB-t patients while 2 PR in 7 RA patients. There was no significant difference in the therapeutic effects and survival between these two groups of patients. These observations suggest that the LD-ACR therapy is effective in some patients with MDS and can be used as an alternative to the low-dose Ara-C therapy.",

author = "Mine Harada and Tsunefumi Shibuya and Takanori Teshima and Masahiro Murakawa and Takashi Okamura and Yoshiyuki Niho and Hisashi Gondo and Shin Hayashi and Koichi Akashi and Kazuo Tamura and Shigeyoshi Makino and Hideyo Natori and Koichiro Egami and Shusuke Hisano and Eiji Morioka and Shuichi Taniguchi and Kazuo Yamazaki and Yujiro Yamano and Fusayuki Omori",

note = "Funding Information: Acknowledgements--This work was supported in part by Grants-in-Aid for Intractable Diseases from the Ministry of Education, Science and Culture, Japan.",

year = "1993",

month = aug,

doi = "10.1016/0145-2126(93)90066-T",

language = "English",

volume = "17",

pages = "629--632",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "8",

}

TY - JOUR

T1 - A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes

AU - Harada, Mine

AU - Shibuya, Tsunefumi

AU - Teshima, Takanori

AU - Murakawa, Masahiro

AU - Okamura, Takashi

AU - Niho, Yoshiyuki

AU - Gondo, Hisashi

AU - Hayashi, Shin

AU - Akashi, Koichi

AU - Tamura, Kazuo

AU - Makino, Shigeyoshi

AU - Natori, Hideyo

AU - Egami, Koichiro

AU - Hisano, Shusuke

AU - Morioka, Eiji

AU - Taniguchi, Shuichi

AU - Yamazaki, Kazuo

AU - Yamano, Yujiro

AU - Omori, Fusayuki

N1 - Funding Information: Acknowledgements--This work was supported in part by Grants-in-Aid for Intractable Diseases from the Ministry of Education, Science and Culture, Japan.

PY - 1993/8

Y1 - 1993/8

N2 - We performed a randomized phase II trial comparing low-dose aclarubicin (LC-ACR) with very low-dose cytosine arabinoside (VLD-AC) in 39 consecutive untreated patients with myelodysplastic syndromes (MDS), including refractory anemia (RA), RA with excess of blasts (RAEB) and RAEB in transformation (RAEB-t). Nineteen patients received the VLD-AC therapy; 2 good responses (GR) and 2 partial responses (PR) were obtained in 11 patients with RAEB and RAEB-t, while 2 PR were obtained in 8 RA patients. Eighteen patients received the LD-ACR therapy; 2 GR and 4 PR were obtained in 11 RAEB/RAEB-t patients while 2 PR in 7 RA patients. There was no significant difference in the therapeutic effects and survival between these two groups of patients. These observations suggest that the LD-ACR therapy is effective in some patients with MDS and can be used as an alternative to the low-dose Ara-C therapy.

AB - We performed a randomized phase II trial comparing low-dose aclarubicin (LC-ACR) with very low-dose cytosine arabinoside (VLD-AC) in 39 consecutive untreated patients with myelodysplastic syndromes (MDS), including refractory anemia (RA), RA with excess of blasts (RAEB) and RAEB in transformation (RAEB-t). Nineteen patients received the VLD-AC therapy; 2 good responses (GR) and 2 partial responses (PR) were obtained in 11 patients with RAEB and RAEB-t, while 2 PR were obtained in 8 RA patients. Eighteen patients received the LD-ACR therapy; 2 GR and 4 PR were obtained in 11 RAEB/RAEB-t patients while 2 PR in 7 RA patients. There was no significant difference in the therapeutic effects and survival between these two groups of patients. These observations suggest that the LD-ACR therapy is effective in some patients with MDS and can be used as an alternative to the low-dose Ara-C therapy.

UR - http://www.scopus.com/inward/record.url?scp=0027168768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027168768&partnerID=8YFLogxK

U2 - 10.1016/0145-2126(93)90066-T

DO - 10.1016/0145-2126(93)90066-T

M3 - Article

C2 - 8355505

AN - SCOPUS:0027168768

SN - 0145-2126

VL - 17

SP - 629

EP - 632

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -

A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this